
E111: PEXIVAS Subsets with Mike Walsh & Mats Junek
About this episode
At ACR23 I had a twitter-disagreement about steroid tapers from PEXIVAS with Mike Walsh, the lead author on the PEXIVAS trial. He kindly agreed to join me for a moderated discussion. Loved hearing his perspective and have to admit he pulled me closer to his practice... but not all the way there. Longer podcast than usual but I prefer to release audio uncut and this took as long as it needed! Hoping y'all enjoy.
Articles referenced during the podcast:
PEXIVAS: https://www.nejm.org/doi/full/10.1056/nejmoa1803537
PEXIVAS DAH Subset: https://www.atsjournals.org/doi/10.1164/rccm.202308-1426OC
Walsh Meta Analysis: https://pubmed.ncbi.nlm.nih.gov/35217545/
Get every episode summarized
Each time The Evidence Based Rheumatology Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Evidence Based Rheumatology Podcast

E133: Obinutuzumab for SLE (ALLEGORY)
The Evidence Based Rheumatology Podcast

E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
The Evidence Based Rheumatology Podcast

E131: A Sham-Controlled Sham of a Trial: RESET-RA
The Evidence Based Rheumatology Podcast

E130: Telitacicept for SLE
The Evidence Based Rheumatology Podcast